Head-to-head · WeighScore
Ark Health vs Ilant Health
The verdict
Too close to call — both grade 56.8/100 (C).
Ark Health and Ilant Health land on the same WeighScore, so neither clears the other on our six graded dimensions. Ark Health sits one line higher on the board (#407 vs #408) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ark Health | Ilant Health |
|---|---|---|
| WeighScore | 56.8/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #407 | #408 |
| Semaglutide | $1,399/mo (brand Ozempic) | Not disclosed |
| Tirzepatide | $1,499/mo (brand Mounjaro) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #407 · C
Strengths
- Broadest menu in the directory — compounded sema/tirz injection, oral sema, brand Ozempic and Mounjaro, Sermorelin, MIC/B12
- Consistent pricing at all dosages — flat rate, no escalation as you titrate up
- Compounded oral semaglutide at $125/mo is competitive for a niche most providers don't offer
- Free expedited shipping included
- Phone support published (uncommon among DTC platforms)
Where it loses points
- States served not listed — can't confirm coverage in your state without contacting support
- LegitScript status not disclosed — no badge or verifiable ID
- FDA compounded-medication disclaimer not displayed
- Medical director / clinical lead not named — only generic 'certified healthcare providers'
- Pharmacy partner not named; 503A vs 503B unspecified
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.